Pacira BioSciences, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

PCRX$36.46+0.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 6. Exhibits

The exhibits listed below are filed or furnished as part of this report.

Exhibit Number	Description
2.1	Agreement and Plan of Merger, dated as of October 8, 2026, by and among Pacira BioSciences, Inc., Viatris Inc. and Peach Purchaser Sub Inc. (1) ** ##
10.1	Fourth Amendment to Manufacturing and Supply Agreement dated August 26, 2026, by and between Pacira Pharmaceuticals, Inc. and Patheon UK Limited.* #
10.2	Pacira BioSciences, Inc. Long-Term Incentive Plan.(2) †
10.3	Pacira BioSciences, Inc. Corporate Annual Bonus Plan Employee Guide.(3) †
10.4	Amendment No. 1 to Pacira BioSciences, Inc. Amended and Restated 2014 Employee Stock Purchase Plan.(4) †
31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.*
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.*
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
101	The following materials from the Quarterly Report on Form 10-Q of Pacira BioSciences, Inc. for the quarter ended September 30, 2026, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets; (ii) the Condensed Consolidated Statements of Operations; (iii) the Condensed Consolidated Statements of Comprehensive Income; (iv) the Condensed Consolidated Statements of Stockholders’ Equity; (v) the Condensed Consolidated Statements of Cash Flows; and (vi) the Condensed Notes to Consolidated Financial Statements.*
104	Cover Page Interactive Data File (Formatted as Inline XBRL and contained in Exhibit 101).

*	Filed herewith.
**	Furnished herewith.
†	Denotes management contract or compensatory plan or arrangement.
#	Certain portions of the exhibit have been omitted pursuant to Rule 601(a)(2) of Regulation S-K. The omitted information (i) is not material and (ii) is the type that the Registrant treats as private or confidential.
##	Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally to the SEC a copy of any omitted exhibits or schedules upon request; provided that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
(1)	Incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K, filed on October 8, 2026.
(2)	Incorporated by reference to Exhibit (e)(26) to the Registrant’s Schedule 14D-9, filed on October 30, 2026.
(3)	Incorporated by reference to Exhibit (e)(27) to the Registrant’s Schedule 14D-9, filed on October 30, 2026.
(4)	Incorporated by reference to Exhibit (e)(28) to the Registrant’s Schedule 14D-9, filed on October 30, 2026.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.